{"title":"埃塞俄比亚风湿性心脏病患者肺动脉高压患病率及相关因素","authors":"Asmamaw Gedefaw, Yihealem Yabebal Ayele, Gebeyaw Wudie, Abiyot Tefera, Agerye Kassa Yirdaw, Tadele Demilew","doi":"10.1186/s12872-025-04476-3","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>In developing countries evidences regarding pulmonary hypertension (PH) in rheumatic heart disease (RHD) patients are lacking, despite being responsible for significant morbidity and mortality. As a result, identifying the factors that influence PH is crucial to improve the quality of care.</p><p><strong>Objective: </strong>To determine prevalence of pulmonary hypertension and its associated factors among rheumatic heart disease patients at the public hospitals of Bahir Dar city, Ethiopia.</p><p><strong>Methods: </strong>An institution based prospective cross-sectional study was conducted among RHD patients who had follow up at the two public hospitals of Bahir Dar city from January 2022 to December 2023. It involved 310 patients selected by systematic random sampling technique. Pretested, structured, and interviewer-administered questionnaires were used to collect sociodemographic and diseases related parameters.Transthoracic echocardiography by cardiologist was used to assess PH. Data were entered using Epidata Manager version 4.6 and analyzed using SPSS version 27. Multivariate logistic regression analysis was used to identify determinants of PH, considering with a p-value of < 0.05 as statically significant, with a 95% confidence interval.</p><p><strong>Results: </strong>The mean systolic pulmonary arterial pressure (sPAP) of the participants was 50.2 mmHg [SD ± 25.0 mmHg]. The prevalence of PH among RHD patients was 56.5% (95% CI 50.9 - 61.9) from which 51.4% had severe PH. Severe mitral valve stenosis (AOR 7.8, 95% CI 2.4-25.7), duration of illness ≥ 3 years (AOR 7.7, 95% CI 2.1-28.5), and diuretics use (AOR 5.6, 95% CI 2.2-14.3) were factors associated with PH. In contrast, valvular intervention (AOR 0.06, 95% CI 0.01-0.29) and LVEF ≥ 50% (AOR 0.14, 95% CI 0.02-0.81) were found to be protective factors.</p><p><strong>Conclusions: </strong>The prevalence of PH among RHD patients in Ethiopia is high and it's associated with delayed presentation & complications. Special attention should be paid to early surgical or percutaneous valvular intervention for those who have indication, before they develop permanent cardiac remodeling and LVFE become reduced. As a result, access to valvular intervention need to be addressed to improve PH related morbidity & mortality among RHD patients in Ethiopia.</p>","PeriodicalId":9195,"journal":{"name":"BMC Cardiovascular Disorders","volume":"25 1","pages":"20"},"PeriodicalIF":2.0000,"publicationDate":"2025-01-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11734543/pdf/","citationCount":"0","resultStr":"{\"title\":\"Prevalence of pulmonary hypertension and associated factors among rheumatic heart disease patients in Ethiopia.\",\"authors\":\"Asmamaw Gedefaw, Yihealem Yabebal Ayele, Gebeyaw Wudie, Abiyot Tefera, Agerye Kassa Yirdaw, Tadele Demilew\",\"doi\":\"10.1186/s12872-025-04476-3\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>In developing countries evidences regarding pulmonary hypertension (PH) in rheumatic heart disease (RHD) patients are lacking, despite being responsible for significant morbidity and mortality. As a result, identifying the factors that influence PH is crucial to improve the quality of care.</p><p><strong>Objective: </strong>To determine prevalence of pulmonary hypertension and its associated factors among rheumatic heart disease patients at the public hospitals of Bahir Dar city, Ethiopia.</p><p><strong>Methods: </strong>An institution based prospective cross-sectional study was conducted among RHD patients who had follow up at the two public hospitals of Bahir Dar city from January 2022 to December 2023. It involved 310 patients selected by systematic random sampling technique. Pretested, structured, and interviewer-administered questionnaires were used to collect sociodemographic and diseases related parameters.Transthoracic echocardiography by cardiologist was used to assess PH. Data were entered using Epidata Manager version 4.6 and analyzed using SPSS version 27. Multivariate logistic regression analysis was used to identify determinants of PH, considering with a p-value of < 0.05 as statically significant, with a 95% confidence interval.</p><p><strong>Results: </strong>The mean systolic pulmonary arterial pressure (sPAP) of the participants was 50.2 mmHg [SD ± 25.0 mmHg]. The prevalence of PH among RHD patients was 56.5% (95% CI 50.9 - 61.9) from which 51.4% had severe PH. Severe mitral valve stenosis (AOR 7.8, 95% CI 2.4-25.7), duration of illness ≥ 3 years (AOR 7.7, 95% CI 2.1-28.5), and diuretics use (AOR 5.6, 95% CI 2.2-14.3) were factors associated with PH. In contrast, valvular intervention (AOR 0.06, 95% CI 0.01-0.29) and LVEF ≥ 50% (AOR 0.14, 95% CI 0.02-0.81) were found to be protective factors.</p><p><strong>Conclusions: </strong>The prevalence of PH among RHD patients in Ethiopia is high and it's associated with delayed presentation & complications. Special attention should be paid to early surgical or percutaneous valvular intervention for those who have indication, before they develop permanent cardiac remodeling and LVFE become reduced. As a result, access to valvular intervention need to be addressed to improve PH related morbidity & mortality among RHD patients in Ethiopia.</p>\",\"PeriodicalId\":9195,\"journal\":{\"name\":\"BMC Cardiovascular Disorders\",\"volume\":\"25 1\",\"pages\":\"20\"},\"PeriodicalIF\":2.0000,\"publicationDate\":\"2025-01-14\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11734543/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"BMC Cardiovascular Disorders\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1186/s12872-025-04476-3\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMC Cardiovascular Disorders","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12872-025-04476-3","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0
摘要
背景:在发展中国家,风湿性心脏病(RHD)患者中肺动脉高压(PH)的证据缺乏,尽管它是造成严重发病率和死亡率的原因。因此,确定影响PH值的因素对于提高护理质量至关重要。目的:了解埃塞俄比亚巴希尔达尔市公立医院风湿性心脏病患者肺动脉高压患病率及其相关因素。方法:对2022年1月至2023年12月在巴希尔达尔市两所公立医院随访的RHD患者进行基于机构的前瞻性横断面研究。采用系统随机抽样方法选取310例患者。使用预测试、结构化和访谈者管理的问卷来收集社会人口学和疾病相关参数。采用心脏科医生的经胸超声心动图评估ph值。使用Epidata Manager 4.6版本输入数据,并使用SPSS 27版本进行分析。考虑到p值,采用多变量logistic回归分析来确定PH的决定因素:参与者的平均收缩压(sPAP)为50.2 mmHg [SD±25.0 mmHg]。RHD患者PH患病率为56.5% (95% CI 50.9 - 61.9),其中51.4%为重度PH。重度二尖瓣狭窄(AOR 7.8, 95% CI 2.4-25.7)、病程≥3年(AOR 7.7, 95% CI 2.1-28.5)和利尿剂使用(AOR 5.6, 95% CI 2.2-14.3)是与PH相关的因素。相反,瓣膜干预(AOR 0.06, 95% CI 0.01-0.29)和LVEF≥50% (AOR 0.14, 95% CI 0.02-0.81)被认为是保护因素。结论:埃塞俄比亚RHD患者中PH的患病率很高,并且与延迟表现和并发症有关。对于那些有适应证的患者,应在发生永久性心脏重构和LVFE降低之前进行早期手术或经皮瓣膜介入治疗。因此,需要解决获得瓣膜干预的问题,以改善埃塞俄比亚RHD患者中PH相关的发病率和死亡率。
Prevalence of pulmonary hypertension and associated factors among rheumatic heart disease patients in Ethiopia.
Background: In developing countries evidences regarding pulmonary hypertension (PH) in rheumatic heart disease (RHD) patients are lacking, despite being responsible for significant morbidity and mortality. As a result, identifying the factors that influence PH is crucial to improve the quality of care.
Objective: To determine prevalence of pulmonary hypertension and its associated factors among rheumatic heart disease patients at the public hospitals of Bahir Dar city, Ethiopia.
Methods: An institution based prospective cross-sectional study was conducted among RHD patients who had follow up at the two public hospitals of Bahir Dar city from January 2022 to December 2023. It involved 310 patients selected by systematic random sampling technique. Pretested, structured, and interviewer-administered questionnaires were used to collect sociodemographic and diseases related parameters.Transthoracic echocardiography by cardiologist was used to assess PH. Data were entered using Epidata Manager version 4.6 and analyzed using SPSS version 27. Multivariate logistic regression analysis was used to identify determinants of PH, considering with a p-value of < 0.05 as statically significant, with a 95% confidence interval.
Results: The mean systolic pulmonary arterial pressure (sPAP) of the participants was 50.2 mmHg [SD ± 25.0 mmHg]. The prevalence of PH among RHD patients was 56.5% (95% CI 50.9 - 61.9) from which 51.4% had severe PH. Severe mitral valve stenosis (AOR 7.8, 95% CI 2.4-25.7), duration of illness ≥ 3 years (AOR 7.7, 95% CI 2.1-28.5), and diuretics use (AOR 5.6, 95% CI 2.2-14.3) were factors associated with PH. In contrast, valvular intervention (AOR 0.06, 95% CI 0.01-0.29) and LVEF ≥ 50% (AOR 0.14, 95% CI 0.02-0.81) were found to be protective factors.
Conclusions: The prevalence of PH among RHD patients in Ethiopia is high and it's associated with delayed presentation & complications. Special attention should be paid to early surgical or percutaneous valvular intervention for those who have indication, before they develop permanent cardiac remodeling and LVFE become reduced. As a result, access to valvular intervention need to be addressed to improve PH related morbidity & mortality among RHD patients in Ethiopia.
期刊介绍:
BMC Cardiovascular Disorders is an open access, peer-reviewed journal that considers articles on all aspects of the prevention, diagnosis and management of disorders of the heart and circulatory system, as well as related molecular and cell biology, genetics, pathophysiology, epidemiology, and controlled trials.